Leprosy Reactions: The Predictive Value of Mycobacterium leprae-Specific Serology Evaluated in a Brazilian Cohort of Leprosy Patients (U-MDT/CT-BR)

STROBE Statement form

	Item No	Recommendation	Lines
Title and abstract	1	(*a*) Indicate the study's design with a commonly used term in the title or the abstract	------
		(*b*) Provide in the abstract an informative and balanced summary of what was done and what was found	23-52
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	126-135
Objectives	3	State specific objectives, including any prespecified hypotheses	129-132
Methods			
Study design	4	Present key elements of study design early in the paper	126-135
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	138-149
Participants	6	(*a*) Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	150-156
		(*b*) For matched studies, give matching criteria and the number of controls per case	Not Applicable
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	142-149 150-156 167-172
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	138-142 173-206
Bias	9	Describe any efforts to address potential sources of bias	150-152
Study size	10	Explain how the study size was arrived at	153-156
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	208-217
Statistical methods	12	(*a*) Describe all statistical methods, including those used to control for confounding	218-223
		(*b*) Describe any methods used to examine subgroups and interactions	Not Applicable
		(*c*) Explain how missing data were addressed	Not Applicable
		(*d*) If applicable, explain how matching of cases and controls was addressed	----
		(*e*) Describe any sensitivity analyses	221
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	-------
		(b) Give reasons for non-participation at each stage	-------

		(c) Consider use of a flow diagram	-------
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	157-166
		(b) Indicate number of participants with missing data for each variable of interest	Not Applicable
Outcome data	15*	Report numbers in each exposure category, or summary measures of exposure	Not Applicable
Main results	16	(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Not Applicable
		(*b*) Report category boundaries when continuous variables were categorized	318-333, 342-354, 363-375
		(*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	--------
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	208-217
Discussion			
Key results	18	Summarise key results with reference to study objectives	267-293
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	257-265
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	411-521
Generalisability	21	Discuss the generalisability (external validity) of the study results	522-528
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	At Plos NTD form

*Give information separately for cases and controls.